Medical Strategy Advisory Board (“MSAB”) to advise DRE on the convergence of expert AI-enabled technology in healthcare and the exponential growth of clinical information
SANTA MONICA, Calif.–(BUSINESS WIRE)–DRE is pleased to welcome four new members to its MSAB. They join Chair, Ameet Nathwani, MD, MRCP, DipPharmMed, MBA in advising DRE on the convergence of expert AI-enabled technology in healthcare and the exponential growth of clinical information.
DRE offers software solutions that enable researchers, scientists and physicians to rapidly discover and analyze data from vast and varied medical information including clinical studies, real world data, and pre-clinical evidence, genomics and more.
“DRE is at the forefront of leveraging technology to accelerate drug discovery and repurposing at a particularly critical time for the healthcare industry,” Dr. Nathwani commented. “The addition of these exceptional leaders to the MSAB will expand our ability to enhance the platform and broaden its impact, ultimately improving health options globally.”
DRE’s CEO Bob Battista commented, “These leaders joined the MSAB because they believe in DRE’s mission to democratize access to medical evidence with carefully applied disciplines of critical appraisal methodologies. Their knowledge will help us advance our solutions to have the biggest and quickest impact on evidence synthesis tools in the scientific community.”
“We greatly appreciate Dr. Nathwani’s leadership on the MSAB and his recruitment of such extraordinary individuals,” stated Joseph A. Boystak, DRE’s Chairman of the Board. DRE’s corporate board will be guided by the MSAB’s expert advice and deep insights for strategic input, further enhancements to our AI-enabled SaaS platform and resource requirements to better serve our clients, physicians and patients worldwide.”
The new MSAB members include:
Calum MacRae, MB, ChB, PhD, BSc
Dr. MacRae is a Professor of Medicine at Harvard Medical School, Co-Director of Genomic Medicine and Vice Chair for Innovation in the Department of Medicine at Brigham and Women’s Hospital.
Frank Rockhold, PhD, ScM, BA
Dr. Rockhold is a Professor of Biostatistics and Bioinformatics at Duke University Medical Center, Affiliate Professor of Biostatistics at Virginia Commonwealth University, and Managing Partner of HunterRockhold, Inc.
David Tovey, MD
Dr. Tovey was the Editor in Chief of The Cochrane Library for over 10 years. In January 2021, he will take over as Co-Editor in Chief for the Journal of Clinical Epidemiology.
Anthony Chang, MD, MBA, MPH, MS
Dr. Chang serves as the Chief Intelligence and Innovation Officer (CIIO) and Medical Director of the Heart Failure Program at Children’s Hospital of Orange County. He is the founder of the Pediatric Cardiac Intensive Care Society (PCICS) that launched the multi-disciplinary focus on cardiac intensive care for children.
DRE is a market leading company in the AI-enabled health technology marketplace that deploys state-of-the-art solutions to identify, synthesize, and analyze complex clinical data into actionable insights. DRE provides instant, continuous search and data analysis across critical functions of Pharmaceutical, Biotech, Life Sciences and Medical Technology companies to optimize their clinical programs. Its technology platform provides DRE’s customers with a Software-as-a-Service (“SaaS”) Insights Engine which empowers them to make better decisions from lab to patient.